Provided by Tiger Trade Technology Pte. Ltd.

Cellectar Biosciences

2.70
-0.2000-6.90%
Post-market: 2.700.00000.00%19:12 EDT
Volume:31.45K
Turnover:88.11K
Market Cap:11.45M
PE:-0.32
High:2.87
Open:2.87
Low:2.70
Close:2.90
52wk High:20.59
52wk Low:2.45
Shares:4.24M
Float Shares:4.06M
Volume Ratio:1.15
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.3544
EPS(LYR):-8.3544
ROE:-170.27%
ROA:-71.01%
PB:1.43
PE(LYR):-0.32

Loading ...

Cellectar Biosciences Inc - Announces Multi-Year Supply Agreement With Ionetix

THOMSON REUTERS
·
Dec 16, 2025

Cellectar Biosciences Announces Strategic Supply Agreement With Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

THOMSON REUTERS
·
Dec 16, 2025

Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies

Reuters
·
Dec 06, 2025

Cellectar BioSciences reports Q3 net loss of $4.4 million

Reuters
·
Nov 13, 2025

Cellectar Biosciences Q3 net loss narrows to $4.4 mln

Reuters
·
Nov 13, 2025

Cellectar BioSciences Reports Q3 2025 Financial Results and Advances Oncology Pipeline

Reuters
·
Nov 13, 2025

Cellectar Biosciences Q3 EPS USD -1.41

THOMSON REUTERS
·
Nov 13, 2025

Cellectar Biosciences Q3 EPS $(1.41) Beats $(2.53) Estimate

Benzinga
·
Nov 13, 2025

Cellectar BioSciences Inc. to Release Third Quarter Financial Results

Reuters
·
Nov 06, 2025

Cellectar Biosciences Inc expected to post a loss of $2.53 a share - Earnings Preview

Reuters
·
Nov 06, 2025

Cellectar Says FDA Grants Rare Pediatric Drug Designation for Iopofosine in High-Grade Glioma

MT Newswires Live
·
Oct 27, 2025

Cellectar Biosciences Inc - May Receive Priority Review Voucher

THOMSON REUTERS
·
Oct 27, 2025

Cellectar Biosciences Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

THOMSON REUTERS
·
Oct 27, 2025

Cellectar Biosciences Inc expected to post a loss of $2.76 a share - Earnings Preview

Reuters
·
Oct 25, 2025

Cellectar Biosciences files to sell 2.1M shares of common stock for holders

TIPRANKS
·
Oct 21, 2025

Cellectar Biosciences presents posters at AACR on CLR 121225, CLR 225

TIPRANKS
·
Oct 14, 2025

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

GlobeNewswire
·
Oct 14, 2025

Cellectar Biosciences Raises $5.8M Through Warrant Exercise

TIPRANKS
·
Oct 11, 2025

Cellectar BioSciences raises 58 million from warrant exercises and issues new inducement warrants totaling 1048094 shares

Reuters
·
Oct 11, 2025

BRIEF-Cellectar Biosciences, Inc. Enters Into Agreements To Raise $5.8 Million

Reuters
·
Oct 07, 2025